Tania Massignan

发表

Redox regulation of surface protein thiols: Identification of integrin α-4 as a molecular target by using redox proteomics

P. Ghezzi, E. Gianazza, V. Bonetto, 2003, Proceedings of the National Academy of Sciences of the United States of America.

An N-terminal Polybasic Domain and Cell Surface Localization Are Required for Mutant Prion Protein Toxicity*

I. Solomon, D. Harris, J. E. Huettner, 2011, The Journal of Biological Chemistry.

Insoluble Mutant SOD1 Is Partly Oligoubiquitinated in Amyotrophic Lateral Sclerosis Mice*

M. Salmona, C. Cheroni, C. Bendotti, 2006, Journal of Biological Chemistry.

Therapeutic Approaches to Prion Diseases : In Vitro Studies with Tetracycline Compounds

G. Forloni, F. Tagliavini, M. Salmona, 2002 .

Redox regulation of cyclophilin A by glutathionylation

P. Ghezzi, L. Mollica, M. Salmona, 2006, Proteomics.

Transglutaminase 2 transamidation activity during first-phase insulin secretion: natural substrates in INS-1E

F. Bertuzzi, M. Alessio, S. La Rosa, 2013, Acta Diabetologica.

Characterization of Detergent-Insoluble Proteins in ALS Indicates a Causal Link between Nitrative Stress and Aggregation in Pathogenesis

M. Strong, M. Salmona, C. Cheroni, 2009, PloS one.

Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity

G. Forloni, M. Salmona, R. Chiesa, 2006, Proteomics.

Mutant Prion Protein Expression Is Associated with an Alteration of the Rab GDP Dissociation Inhibitor α (GDI)/Rab11 Pathway*

D. Harris, M. Salmona, R. Chiesa, 2009, Molecular & Cellular Proteomics.

Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse.

M. Salmona, C. Bendotti, E. Gianazza, 2007, Biochemical and biophysical research communications.

A Small‐Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity

M. Barreca, A. Altieri, I. Andreev, 2017, ChemMedChem.

dissociation inhibitor alpha (GDI)/Rab11 pathway

D. Harris, M. Salmona, R. Chiesa, 2009 .

The neurotoxicity of prion protein (PrP) peptide 106–126 is independent of the expression level of PrP and is not mediated by abnormal PrP species

R. S. Stewart, G. Forloni, D. Harris, 2005, Molecular and Cellular Neuroscience.

The Toxicity of a Mutant Prion Protein Is Cell-Autonomous, and Can Be Suppressed by Wild-Type Prion Protein on Adjacent Cells

G. Forloni, D. Harris, R. Chiesa, 2012, PloS one.

A Drug-Based Cellular Assay (DBCA) for studying cytotoxic and cytoprotective activities of the prion protein: A practical guide.

D. Harris, Tania Massignan, E. Biasini, 2011, Methods.

Synthetic Miniprion PrP106*

G. Forloni, F. Tagliavini, M. Salmona, 2002, The Journal of Biological Chemistry.

Erratum: Redox regulation of surface protein thiols: Identification of integrin α-4 as a molecular target by using redox proteomics (Proceedings of the National Academy of Sciences of the United States of America (December 9, 2003) 100, 25 (14737-14741))

P. Ghezzi, V. Bonetto, F. Casoni, 2004 .

IL-7-induced phosphorylation of the adaptor Crk-like and other targets.

Q. Jiang, F. Aiello, S. Durum, 2018, Cellular signalling.

The hydrophobic core region governs mutant prion protein aggregation and intracellular retention.

R. Chiesa, Elena Restelli, L. Tapella, 2010, The Biochemical journal.

Glutathionylation of human thioredoxin: A possible crosstalk between the glutathione and thioredoxin systems

P. Ghezzi, A. Holmgren, M. Salmona, 2002, Proceedings of the National Academy of Sciences of the United States of America.

An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein

R. Nonno, M. Gobbi, J. Castilla, 2017, PloS one.

PHARMACOLOGICAL PROTEIN INACTIVATION BY TARGETING FOLDING INTERMEDIATES

S. Orioli, P. Faccioli, M. Pennuto, 2020, bioRxiv.

A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein

R. Nonno, M. Gobbi, J. Castilla, 2016, Scientific Reports.

Identification of compounds inhibiting prion replication and toxicity by removing PrPC from the cell surface

A. Dalle Vedove, P. Gatto, V. Bonetto, 2020, Journal of neurochemistry.

Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes.

G. Mora, S. Pozzi, C. Bendotti, 2015, Brain : a journal of neurology.

Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies

S. Hornemann, A. Aguzzi, I. Zerr, 2021, Science advances.

Pharmacological inactivation of the prion protein by targeting a folding intermediate

S. Orioli, P. Faccioli, M. Pennuto, 2021, Communications biology.

The N-Terminal, Polybasic Region of PrPC Dictates the Efficiency of Prion Propagation by Binding to PrPSc

P. Saá, S. Supattapone, D. Harris, 2012, The Journal of Neuroscience.

Ligands binding to the cellular prion protein induce its protective proteolytic release with therapeutic potential in neurodegenerative proteinopathies

S. Hornemann, A. Aguzzi, I. Zerr, 2021, bioRxiv.

A Mutant Prion Protein Sensitizes Neurons to Glutamate-Induced Excitotoxicity

J. Luebke, P. Toselli, I. Solomon, 2013, The Journal of Neuroscience.

Protein Nitration in a Mouse Model of Familial Amyotrophic Lateral Sclerosis

M. Salmona, C. Cheroni, C. Bendotti, 2005, Journal of Biological Chemistry.

Identification of a Druggable Intermediate along the Folding Pathway of the SARS-CoV-2 Receptor ACE2

P. Faccioli, G. Lolli, L. Pieri, 2020, 2004.13493.

Lowering the Expression of the SARS-CoV-2 Receptor ACE2 by Drug Repositioning.

P. Faccioli, G. Lolli, L. Pieri, 2020 .

A Novel, Drug-based, Cellular Assay for the Activity of Neurotoxic Mutants of the Prion Protein*

R. S. Stewart, I. Solomon, D. Harris, 2009, The Journal of Biological Chemistry.